Genes and regulatory pathways involved in persistence of dormant micro-tumors.

作者: Nava Almog

DOI: 10.1007/978-1-4614-1445-2_1

关键词: Tumor progressionCancer cellBiologyTranscriptomeExperimental pathologyTumor microenvironmentAngiogenesisCancer researchRegulation of gene expressionDormancy

摘要: Micro-tumors can remain dormant for prolonged periods of time before they switch and enter the rapid growth phase. This initial stage in tumor progression is clearly understudied. In spite high prevalence, significant clinical implications increased interest by research community, dormancy still poorly understood. The topic also suffers from a lack definition an agreed upon terminology to describe it. Additionally, number reproducible experimental models available studying indolence human micro-tumors quite limited. Here, we development general class vivo indolent tumors how these be used elucidate molecular cellular mechanisms involved regulation dormancy. consist cell lines that form microscopic cancerous lesions mice. Although contain viable fully malignant cancer cells, do not expand size but occult until eventually spontaneously become fast-growing tumors. Consistent with Judah Folkman’s vision will acquire ability recruit new functional blood vessels, period associated impaired angiogenic capacity. Such dissecting host tumor-derived regulatory Understanding process which overcome constraints emerge dormancy, resuming expansion, may provide insights into novel strategies prolong state or block formation early stages, are physically detected symptomatic.

参考文章(66)
Benjamin D. Hedley, Ann F. Chambers, Tumor dormancy and metastasis. Advances in Cancer Research. ,vol. 102, pp. 67- 101 ,(2009) , 10.1016/S0065-230X(09)02003-X
Folkman J, The role of angiogenesis in tumor growth. Seminars in Cancer Biology. ,vol. 3, pp. 65- 71 ,(1992)
Judah Folkman, Birgit M. Kräling, Catherine E. Butterfield, Blair Marshall, Timothy Browder, Michael S. O’Reilly, Bin Shi, Antiangiogenic Scheduling of Chemotherapy Improves Efficacy against Experimental Drug-resistant Cancer Cancer Research. ,vol. 60, pp. 1878- 1886 ,(2000)
Romano Demicheli, Michael W Retsky, William JM Hrushesky, Michael Baum, Tumor dormancy and surgery-driven interruption of dormancy in breast cancer: learning from failures. Nature Reviews Clinical Oncology. ,vol. 4, pp. 699- 710 ,(2007) , 10.1038/NCPONC0999
PHILIP HAHNFELDT, JUDAH FOLKMAN, LYNN HLATKY, Minimizing long-term tumor burden: the logic for metronomic chemotherapeutic dosing and its antiangiogenic basis. Journal of Theoretical Biology. ,vol. 220, pp. 545- 554 ,(2003) , 10.1006/JTBI.2003.3162
Bruno Quesnel, Dormant tumor cells as a therapeutic target? Cancer Letters. ,vol. 267, pp. 10- 17 ,(2008) , 10.1016/J.CANLET.2008.02.055
E. A. K. Alsabti, Tumor dormancy: a review. Journal of Cancer Research and Clinical Oncology. ,vol. 95, pp. 209- 220 ,(1979) , 10.1007/BF00410641
Louis M. Sherwood, Edith E. Parris, Judah Folkman, Tumor Angiogenesis: Therapeutic Implications New England Journal of Medicine. ,vol. 285, pp. 1182- 1186 ,(1971) , 10.1056/NEJM197111182852108
Judah Folkman, Raghu Kalluri, Cancer without disease Nature. ,vol. 427, pp. 787- 787 ,(2004) , 10.1038/427787A